Background: Animal studies suggest that the anti-inflammatory effect of methotrexate (MTX) is mediated by increased adenosine concentrations.

Objective: To assess the effect of MTX on the vasodilator effects of adenosine and the nucleoside uptake inhibitor, dipyridamole, in humans in vivo as a marker for changes in adenosine kinetics.

Methods: Ten patients with active arthritis were treated with MTX (15 mg/week). Measurements were performed before and after 12 weeks of treatment. At these time points, the activity of adenosine deaminase was measured in isolated lymphocytes, and forearm blood flow (FBF) was determined by venous occlusion plethysmography during administration of adenosine and dipyridamole into the brachial artery.

Results: The V_{max} of adenosine deaminase in lymphocytes was reduced by MTX treatment (p < 0.05). MTX significantly enhanced vasodilator response to adenosine (0.5 and 1.5 μg/min/dl of forearm tissue; mean (SE) FBF ratio increased from 1.2 (0.2) to 1.4 (0.2) and 2.2 (0.2) ml/dl/min, respectively, before and from 1.3 (0.1) to 1.8 (0.2) and 3.2 (0.5) ml/dl/min during MTX treatment; p < 0.05). Also, dipyridamole-induced vasodilatation (30 and 100 μg/min/dl) was enhanced by MTX (FBF ratio increased from 1.2 (0.2) to 1.5 (0.3) and 1.8 (0.2), respectively, before and from 1.3 (0.1) to 1.8 (0.2) and 2.4 (0.4) during MTX treatment; p < 0.05).

Conclusions: MTX treatment inhibits deamination of adenosine and potentiates adenosine-induced vasodilatation. Also dipyridamole-induced vasodilatation is enhanced by MTX treatment, suggesting an increased extracellular formation of adenosine. These effects on the adenosine kinetics in humans may contribute to the therapeutic efficacy of MTX.

PATIENTS AND METHODS

Subjects
Adult outpatients with active arthritis in whom MTX treatment was indicated according to their treating rheumatologist were asked to participate. Concomitant use of other DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids was not allowed to be changed from 1 month before the start of treatment until the end of the study. Exclusion criteria were pregnancy, breast feeding, asthma, alcohol abuse (>20 units/week), raised liver enzymes (alanine aminotransferase (ALT) >3 times the upper limit), renal insufficiency (estimated clearance <50 ml/min), thrombocytopenia (<120x10^9/l), or leucocytopenia (<3.5x10^9/l). Patients were not allowed to enter the study if they had been treated previously with MTX, or if they were treated currently with sulfasalazine, dipyridamole, folic acid or folinic acid. Folic acid supplementation was not given in the 12 week treatment period to avoid any possible interference with our measurements.

Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; ALT, alanine aminotransferase; AMP, adenosine monophosphate; CRP, C reactive protein; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; FBF, forearm blood flow; HPLC, high performance liquid chromatography; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug
The study protocol was approved by the Institutional Review Board of the Radboud University Nijmegen Medical Centre and the investigation conforms with the principles outlined in the Declaration of Helsinki. Ten patients agreed to participate and signed written informed consent before participation. Seven patients were diagnosed with rheumatoid arthritis, two patients with psoriatic arthritis, and one patient with an unspecified oligoarthritis. Table 1 shows other baseline characteristics.

### Experimental protocol

All patients started oral treatment with MTX at a dose of 15 mg/week during the study period. Vasodilator effects of adenosine and dipyridamole were assessed before and 12 weeks after the start of treatment, 2 hours after the intake of the weekly MTX dose. All experiments were performed in the morning in a temperature controlled laboratory (23°C). Participants were asked to abstain from products containing caffeine for at least 24 hours before each experiment because caffeine is an effective adenosine receptor antagonist.17 NSAIDs were discontinued for at least 24 hours before each experiment to avoid any influence of cyclo-oxygenase inhibition on vascular function.

On these visits the disease activity score was obtained by a rheumatologist (PB), and blood was drawn for determination of ALT, alkaline phosphatase, creatinine, total blood count, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), total plasma homocysteine, and the activity of the non-dominant arm was cannulated with a 20-gauge catheter (Angiocath, Deseret Medical, UT, USA) for intrarterial drug administration (automatic syringe infusion pump, type STC-521, Terumo Corporation, Tokyo, Japan) and blood pressure recording (Hewlett Packard GmbH, Böblingen, Germany). Forearm blood flow (FBF) was registered simultaneously on both arms by venous occlusion plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, Hokanson, Inc, Washington, USA), as previously described.19 Each drug dose was infused for 5 minutes and FBF was recorded three times a minute during the last 2 minutes of each infusion. Before each drug infusion, a wrist cuff was inflated to 200 mm Hg to exclude hand circulation from the measurements.

Baseline FBF was assessed during infusion of saline into the brachial artery. Subsequently, adenosine was infused in a dose of 0.5 and 1.5 μg/min/dl of forearm tissue. After 30 minutes of washout, baseline FBF was measured again during infusion of saline and, finally, dipyridamole was infused in a dose of 30 and 100 μg/min/dl.

### Analytical methods

Total plasma homocysteine was determined using reversed phase high performance liquid chromatography (HPLC), as previously described.20 For the determination of adenosine deaminase activity, erythrocytes were isolated from freshly drawn blood by centrifugation, washed two times in saline, and resuspended in MOPS buffer (10 mM MOPS, 0.9% NaCl, pH 7.4) to obtain a 20% (vol/vol) solution. Subsequently, the

---

**Table 1** Baseline characteristics of the patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>5/5</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.2 (12.0)</td>
</tr>
<tr>
<td>Disease activity</td>
<td>4.0 (1.1)</td>
</tr>
<tr>
<td>Body mass index</td>
<td>24.7 (5.4)</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>88.0 (56.4)</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>5.4 (0.6)</td>
</tr>
<tr>
<td>Plasma glucose (mmol/l)</td>
<td>5.3 (0.5)</td>
</tr>
</tbody>
</table>

**Table 2** Laboratory values and haemodynamic measures

<table>
<thead>
<tr>
<th>Variable</th>
<th>Before methotrexate</th>
<th>During methotrexate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (U/l)</td>
<td>20 (11)</td>
<td>45 (24)*</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/l)</td>
<td>77 (17)</td>
<td>75 (23)</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>88 (56)</td>
<td>83 (46)</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>24 (48)</td>
<td>10 (15)</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>15 (18)</td>
<td>16 (22)</td>
</tr>
<tr>
<td>Homocysteine (mmol/l)</td>
<td>8.1 (0.8)</td>
<td>7.7 (1.1)</td>
</tr>
<tr>
<td>Leucocytes (×10⁹/l)</td>
<td>7.8 (2.8)</td>
<td>7.1 (2.4)</td>
</tr>
<tr>
<td>Thrombocytes (×10⁹/l)</td>
<td>253 (92)</td>
<td>278 (88)</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>142 (20)</td>
<td>139 (18)</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>70 (7)</td>
<td>70 (9)</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>65 (12)</td>
<td>66 (13)</td>
</tr>
<tr>
<td>Homocysteine (μmol/l)</td>
<td>10.6 (4.1)</td>
<td>14.9 (4.9)*</td>
</tr>
</tbody>
</table>

Results are shown as mean (SD). *p<0.01 for the effect of methotrexate. SBP, systolic blood pressure; DBP, diastolic blood pressure.
erythrocytes were lysed by adding six volumes of cold distilled water for 5 minutes. After centrifugation for 10 minutes at 4°C the supernatant was stored at −70°C until analysis. Lymphocytes were isolated by Ficoll-Paque centrifugation and were lysed with M-PER mammalian protein extraction reagent in the presence of Halt protease inhibitor cocktail and EDTA solution. After incubation for 10 minutes (22°C), and centrifugation for 15 minutes, the supernatant was stored at −70°C until analysis.

For determination of adenosine deaminase activity, adenosine was added to lysate in a final concentration of 0, 25, 50, 100, 200, and 300 μmol/l at 37°C. Each 200 μl of incubation mixture contained 25 μl cellular lysate and 50 mM Tris-HCl (pH 7.4). After 15 minutes the reaction was stopped by the addition of 50 μl 1.5 M HClO4 followed by centrifugation (3 minutes). Subsequently, 125 μl of the supernatant was mixed with 125 μl trioctylamine in chloroform, and after centrifugation (3 minutes) 50 μl of the neutralised upper layer was used for HPLC analysis of inosine and hypoxanthine with ultraviolet detection.

Data analysis
All data are shown as mean (SD) unless stated otherwise. For each patient, V max and K m values of adenosine deaminase were calculated according to Michaelis-Menten kinetics (GraphPad Prism 4 for Windows). Activity was related to the total protein content in lymphocytes and to the protein content of the membranous fraction in erythrocytes, as determined by the Lowry assay. The effect of MTX treatment on laboratory values and disease activity scores was calculated using a Wilcoxon signed ranks test as not all variables showed a Gaussian distribution.

FBF was measured in both arms simultaneously and the ratio of the FBF in the experimental arm to the control arm (FBF ratio) was calculated to adjust for random changes unrelated to the local stimulus.21 The effect of MTX treatment on the vasodilator response to adenosine and dipyridamole was calculated using analysis of variance for repeated measures (SPSS for windows, release 12.0.1).

RESULTS
One patient was excluded from analysis because MTX treatment had to be discontinued as a result of a rise in ALT activity during the study. The disease activity score was not significantly decreased by MTX (from 4.0 (1.1) to 3.2 (2.0), n = 9, p > 0.1). Plasma concentrations of CRP and haemoglobin tended to decrease during MTX treatment (table 2, p = 0.1). ALT activity and total plasma homocysteine concentration were significantly increased by MTX treatment (table 2). Other biochemical or haemodynamic measures did not change significantly.

In lymphocytes, but not in erythrocytes, the V max value of the enzyme adenosine deaminase was significantly decreased by MTX treatment, whereas K m values were not significantly affected (table 3).

Baseline FBF in the experimental arm was similar on both occasions (2.9 (0.9) ml/min/dl before and 2.9 (0.8) ml/min/dl during MTX treatment, p > 0.1). Also on both occasions, FBF completely returned towards baseline levels after the 30 minute period between the adenosine and dipyridamole infusions, and MTX treatment did not significantly affect FBF in the control arm (data not shown). MTX treatment resulted in a significant enhancement of both adenosine-induced vasodilatation and dipyridamole-induced vasodilatation (p<0.05; fig 2).

DISCUSSION
In this study we demonstrated in humans in vivo that MTX treatment inhibits adenosine deaminase. Also, adenosine-induced forearm vasodilatation was significantly potentiated by MTX. This might be due to the decreased intracellular deamination of adenosine, because it was previously shown that adenosine deamination rather than transport of adenosine over the cellular membrane is rate limiting for the overall catabolism of adenosine.22 We also showed that dipyridamole-induced vasodilatation is potentiated by MTX treatment. This observation indicates that, besides inhibition of
intracellular degradation, also extracellular formation of endogenous adenosine is increased, which is compatible with previous in vitro findings.\textsuperscript{23} In conclusion, we demonstrated for the first time in humans in vivo that treatment with MTX potentiates adenosine A\textsubscript{2A} receptor mediated effects.

The effect of MTX on the metabolism of adenosine was first described by Cronstein \textit{et al} in human fibroblasts and endothelial cells, pretreatment with MTX increases extracellular adenosine. Recently, it was demonstrated that in a rat model of adjuvant arthritis, adenosine receptor antagonists completely abolish the anti-inflammatory effects of MTX.\textsuperscript{24} Moreover, in adenosine A\textsubscript{2A} and A\textsubscript{3} receptor knockout mice, MTX treatment no longer induces any anti-inflammatory effects.\textsuperscript{25}

Human in vivo data on the potential role of adenosine in the mechanism of action of MTX are scarce, controversial, and indirect. Two recent reports suggest that a high intake of caffeinated products diminishes the antiinflammatory effect of MTX.\textsuperscript{8, 9} As caffeine is an effective adenosine receptor antagonist already at concentrations reached after regular coffee consumption,\textsuperscript{22} this is consistent with a role for adenosine receptor stimulation in the mechanism of action of MTX. Interventional studies which determined adenosine concentration before and after administration of MTX provided controversial results, and most studies showed negative results.\textsuperscript{10–14} An important reason for these inconsistent and mostly negative results is the duration of MTX treatment. It is necessary to give MTX for several days to weeks to permit polyglutamation and intracellular accumulation of 5-aminomimidazole-4-carboxamide ribonucleotide (AICAR), which is required for enhanced adenosine formation.\textsuperscript{20} In contrast, in most previous studies, adenosine concentrations were determined after at most 1 day\textsuperscript{11–13} or a few days.\textsuperscript{14} Also, reliable measurement of adenosine is highly cumbersome as its half-life is less than 1 second and the endothelium constitutes an active metabolic barrier for adenosine, resulting in a functional compartmentalisation of adenosine.\textsuperscript{15–18} In the present study, we gave MTX for 12 weeks and bypassed the methodological difficulties of adenosine determination by using adenosine- and dipyridamole-induced vasodilatation as a reflection of adenosine degradation and formation, respectively.

The mechanism by which MTX affects the kinetics and dynamics of adenosine has partially been elucidated by previous animal studies. Most probably, MTX interferes with the de novo purine synthesis pathway in cells.\textsuperscript{1, 25} Polyglutamates of MTX, the long lived intracellular metabolites of MTX, are potent competitive inhibitors of the enzyme AICAR transformylase, resulting in the intracellular accumulation of AICAR\textsuperscript{29} (fig 1). In turn, it has been shown in vitro that AICARiboside inhibits catalytic activity of adenosine deaminase,\textsuperscript{25, 30} and AICARibotide inhibits AMP deaminase.\textsuperscript{25} Morabito \textit{et al} showed that the anti-inflammatory effects of MTX could be abolished by inhibition of ecto-5'-nucleotidase,\textsuperscript{25} emphasising the importance of extracellular conversion of AMP to adenosine. It was suggested that inhibition of AMP deaminase promotes release of adenosine nucleotides, by an as yet unidentified mechanism, which are converted by extracellular 5'-nucleotidase to adenosine (fig 1).

Our study provides additional mechanistic insight, which links up nicely with the abovementioned previous findings. It was previously shown in humans that MTX treatment decreases the activity of adenosine deaminase. However, the effects of MTX on the $V_{\text{max}}$ and $K_m$ values of this enzyme were not assessed.\textsuperscript{31} The present study showed that MTX decreases the $V_{\text{max}}$ but not the $K_m$ of adenosine deaminase in lymphocytes. Unfortunately, from these results it cannot be concluded whether this observed change is due to direct non-competitive enzyme inhibition or decreased enzyme levels, or whether this reflects changes in lymphocyte subpopulations, which could differ in their adenosine deaminase activity.\textsuperscript{22}

To provide further evidence that MTX modulates adenosine metabolism by interfering with de novo purine synthesis, we also determined the activity of adenosine deaminase in erythrocytes, a cell type that lacks the capacity for de novo purine synthesis.\textsuperscript{32} Indeed, in these cells we observed no change of activity of adenosine deaminase during MTX treatment. Unfortunately, we were not able to assess enzymatic activity of other enzymes involved in purine metabolism, such as AMP deaminase and ecto-5'-nucleotidase. It has to be realised that erythrocytes are responsible for the bulk of breakdown of circulating adenosine and that therefore adenosine deamination in lymphocytes probably only has a minor role in the observed increased adenosine-induced vasodilatation in our study. However, endothelial cells and vascular smooth muscle cells contribute significantly to adenosine metabolism.\textsuperscript{33} We postulate that in these cells, adenosine deaminase activity is also reduced, resulting in an increased adenosine concentration which can stimulate adenosine receptors on these cells. In contrast with the breakdown of circulating adenosine, lymphocytes may have an important role in the regulation of adenosine concentration in areas of inflammation. Therefore, the decreased adenosine deaminase activity in lymphocytes could contribute to the anti-inflammatory effect of MTX.

Additional mechanistic information was obtained from the in vivo part of this study. As dipyridamole prevents cellular uptake of endogenous adenosine, it increases the extracellular concentration of adenosine at a rate which is proportional to extracellular formation of adenosine. We have demonstrated previously that dipyridamole-induced vasodilatation in humans is indeed due to inhibition of cellular adenosine uptake: dipyridamole potentiates the vasodilator response to adenosine.\textsuperscript{34} It increases the adenosine concentration in the forearm venous effluent during administration of adenosine into the brachial artery,\textsuperscript{35} and dipyridamole-induced vasodilatation (100 pg/min/dl) is inhibited by the adenosine receptor antagonist theophylline.\textsuperscript{36} The present study shows that dipyridamole-induced vasodilatation is significantly enhanced during MTX treatment. This finding translates the previous in vitro finding of increased extracellular dephosphorylation of AMP during treatment with MTX to the human in vivo situation.

The present study showed that MTX treatment potentiates the vasodilator effect of adenosine. It has to be realised that adenosine receptor stimulation not only inhibits inflammation and induces vasodilatation but also initiates various cardiovascular effects, such as negative inotropic and chronotropic cardiac effects, presynaptic inhibition of sympathetic neurotransmitter release, inhibition of vascular smooth muscle cell proliferation, and inhibition of thrombocyte aggregation.\textsuperscript{37} Also, adenosine receptor stimulation renders the myocardium more resistant to ischaemia and reperfusion injury.\textsuperscript{38} Taken together, these effects have the potential to protect the heart during ischaemia and prevent or slow down the process of atherosclerosis. Patients with rheumatoid arthritis have a higher incidence of cardiovascular disease than the general population.\textsuperscript{39, 40} Interestingly, a recent study suggested that the beneficial effect of MTX on cardiovascular mortality is better than that of other antirheumatic drugs,\textsuperscript{41} although another study did not find this benefit.\textsuperscript{42} When considering the abovementioned cardiovascular effects of adenosine, one can easily appreciate that increased adenosine receptor stimulation could be responsible for this beneficial cardiovascular effect of MTX. Indeed, it was shown previously
in canine hearts that MTX limits myocardial infarct size via adenosine dependent mechanisms. Finally, the potential limitations of our study need to be discussed. It has to be realised that due to the use of a clinical study population in need of immediate treatment the design of the present study was open label and non-randomised. In healthy volunteers a more sophisticated design would have been possible, but in our opinion it is unethical to give MTX to healthy volunteers for a long time. We ensured that the use of other (anti-inflammatory) drugs was kept constant during the study period, in order to prevent confounding by other drugs. Finally, plasma homocysteine concentration needs to be considered as a determinant of adenosine-induced vasodilation. MTX treatment increases plasma homocysteine concentration by interfering with folate dependent remethylation of homocysteine. Any increase in plasma homocysteine, in turn, could stimulate synthesis of S-adenosylhomocysteine at the expense of free adenosine, as we previously described. Also, hyperhomocysteinaemia induces endothelial dysfunction. Fortunately, these potential effects of homocysteine on vascular reactivity are opposite to our present findings, and therefore our conclusion would have been even more convincing if we had been able to correct for the rise in homocysteine.

Our study adds important human in vivo data to the growing body of evidence that adenosine is an important mediator of the therapeutic efficacy of MTX in patients with rheumatoid arthritis. These insights provide potential alternative targets for pharmacological intervention in these patients, such as adenosine uptake inhibition. Dipyridamole, either alone or added to MTX, also increases extracellular endogenous adenosine and thus would also be expected to suppress inflammation in this patient group. To our knowledge, this potential anti-inflammatory effect of dipyridamole has never been systematically studied in a clinical population.

ACKNOWLEDGEMENTS

REFERENCES
35. van Ginneken EE, Ronen GA, Beggel FF, Smits P. Adenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by

www.annrheumdis.com


Methotrexate modulates the kinetics of adenosine in humans in vivo

N P Riksen, P Barrera, P H H van den Broek, P L C M van Riel, P Smits and G A Rongen

Ann Rheum Dis 2006 65: 465-470 originally published online November 24, 2005
doi: 10.1136/ard.2005.048637

Updated information and services can be found at:
http://ard.bmj.com/content/65/4/465

References
This article cites 43 articles, 19 of which you can access for free at:
http://ard.bmj.com/content/65/4/465#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Biological agents (545)
- Degenerative joint disease (4641)
- Drugs: musculoskeletal and joint diseases (700)
- Musculoskeletal syndromes (4951)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/